Low FODMAP Plus PEG 3350 for the Treatment of Patients With Irritable Bowel Syndrome-Constipation

Consecutive patients with Irritable Bowel Syndrome with Constipation (IBS-C) will be recruited from the outpatient clinics of the University of Michigan Health System. Eligible patients will be asked to participate in a study that will test the efficacy the PEG 3350 + a diet low in fermentable oligo, di, monosaccharides, and polyols (FODMAP) vs. PEG 3350 plus sham diet. Blinding dietary advice trials is challenging and therefore the sham diet was based on the criteria set forth by Staudacher et al. which emphasizes that the diet must give the impression that is the true intervention diet with similar restrictions, modifications, and time intensity without impacting the intake of essential nutrients, fiber, and FODMAPs. An example of the sham diet's carbohydrates includes: apples, bananas, and pears, and wheat. Oranges, raspberries, strawberries and rice would not be allowed. Additionally, the physicians analyzing the data will be blinded as to which group the patients were randomized.

Study Overview

• Status: Recruiting
• Conditions: Irritable Bowel Syndrome Characterized by Constipation
• Intervention / Treatment: Other: Low FODMAP diet/PEG 3350; Other: sham diet/PEG 3350

Detailed Description

A. Specific Aims: While a diet low in fermentable oligo, di, monosaccharides and polyols (FODMAPs) has gained popularity as a treatment for patients with Irritable Bowel Syndrome and diarrhea (IBS-D), the impact of this diet on patients with IBS and constipation (IBS-C) is unknown. We propose a randomized, controlled trial in IBS-C patients to compare the efficacy of PEG 3350 and the low FODMAP diet to PEG 3350 and a sham diet. We hypothesize that:

1. The PEG 3350 and low FODMAP diet group will achieve greater improvements in abdominal symptoms including pain, discomfort, and bloating than the group receiving PEG 3350 and the sham diet.
2. The PEG 3350 and low FODMAP diet group will achieve greater improvements in IBS related quality of life and anxiety than the group receiving PEG 3350 and the sham diet.
3. Both strategies will improve constipation related complaints including stool frequency, stool consistency and straining to a similar degree.

We plan to test our central hypothesis and, thereby, accomplish the objective of this application by pursuing the following 2 specific aims:

Aim 1: Compare the proportion of patients with IBS-C on a diet of low FODMAP diet plus PEG 3350 vs. sham diet plus PEG 3350 reporting an improvement of abdominal pain. Our working hypothesis is that a higher proportion of patients randomized to the low FODMAP diet plus PEG 3350 will experience a reduction in the abdominal pain when compared to PEG 3350 plus sham diet alone.

Aim 2: Compare the efficacy of the low FODMAP diet plus PEG 3350 vs. sham diet plus PEG 3350 on pre-specified key clinical and disease specific quality of life endpoints in patients with IBS-C. Through our randomized controlled trial, we will assess the impact of the dietary interventions on stool consistency, stool frequency, and bloating and quality of life endpoints.

A positive result to this study would have significant impact on the treatment of patients with IBS by expanding the indications for the low FODMAP diet to all affected patients, regardless of bowel subtype. This would be particularly relevant to IBS-C patients for whom we currently have few evidence-based diet recommendations outside of increasing fiber intake.

• Study Type: Interventional
• Enrollment (Anticipated): 78
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Stacy Menees, MD, MS; Phone Number: 734-232-3739; Email: sbartnik@med.umich.edu
• Study Contact Backup: Name: Amy Liu, BS; Phone Number: 734-647-4794; Email: liuyalie@med.umich.edu

Study Locations

• United States
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • Recruiting
      • University of Michigan
      • Contact: Stacy Menees, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subjects aged 18 and older meeting the Rome IV criteria for IBS-C*:

• Recurrent abdominal pain, on average, at least 1 day/week in the last 3 months, associated with two or more of the following:

1. related to defecation
2. associated with a change in the frequency of stool (reduction of stools)
3. associated with a change in the form of stool (hard or lumpy stools) AND >25% hard stools and <25% loose stools * Criteria fulfilled for the last 3 months

Exclusion Criteria:

• any other IBS subtype other than IBS-C
• >3 spontaneous bowel movements during the last 7 days of run-in
• Have cognitive dysfunction or unable to understand or provide written informed consent
• Pregnancy (evaluated by self-report)
• Comorbid medical problems that may affect gastrointestinal transit or motility:
• Inflammatory bowel disease
• Extra-intestinal disease known to affect the gastrointestinal system (i.e., scleroderma, unstable thyroid disease, etc.)
• Severe renal or hepatic disease
• Previous abdominal surgery other than appendectomy, cholecystectomy, and gynecologic/urologic surgery if performed more than six months prior to enrollment
• Previous treatment with the low FODMAP diet under a dietician guidance
• Concurrent medications not permitted including probiotics, antibiotics, prescription or over-the-counter medication for IBS, and narcotics
• New antidepressant use (less than 3 months on stable dose)
• Active participation in another form of dietary therapy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Low FODMAP diet plus PEG 3350; Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax).	Other: Low FODMAP diet/PEG 3350; Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.; Other Names: low FODMAP diet
Sham Comparator: Sham diet plus PEG 3350; Subjects will follow a sham diet and will take PEG 3350 (Miralax).	Other: sham diet/PEG 3350; Subjects will follow a sham diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.; Other Names: sham diet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvement of abdominal pain as measured by 11-point numerical rating scale	Compare the proportion of patients with IBS-C on a diet of low FODMAP diet plus PEG 3350 vs. sham diet plus PEG 3350 reporting an improvement of abdominal pain. It is defined 30% reduction in abdominal pain during weeks 3 & 4 of each diet compared with baseline using an 11-point numerical rating scale (NRS) (0-no pain, 11-intolerable pain). Appropriate between-group statistical comparisons will be conducted.	during weeks 3 and 4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Bloating	The change in mean score from baseline on the daily 11-point NRS averaged over each treatment week for bloating severity will be compared between the 2 groups.	each treatment week (4 weeks)
abdominal discomfort	30% reduction in abdominal discomfort during weeks 3 & 4 of each diet compared with baseline using an 11-point NRS. Appropriate between-group statistical comparisons will be conducted.	during weeks 3 and 4
Mean number of SBMs per day	These will be measured in the last treatment week (the 7-day period before visit 4): The proportion of responders between the 2 groups will be compared. An SBM was defined as a bowel movement that occurred without the use of rescue medication or ≥24 h after the use of rescue medication.	week 4
Mean weekly number of spontaneous complete bowel movements	These will be tallied in the last treatment week (the 7-day period before visit 4):(SCBMs; derived from the number of SBMs without a feeling of incomplete evacuation)	last treatment week
Composite endpoint: Full responder was defined as a patient with >3 SBM per week, an increase of ≥1 SBM per week and >30% pain reduction.	during weeks 3 & 4	during weeks 3 & 4
stool consistency	a responder will be defined as one who reports an increase in mean daily BSFS value of 1 or more compared to baseline for ≥2 of 4 treatment weeks. The proportion of responders between the 2 groups will be compared. Between group differences in the proportion of patients with an increase in BSFS value of ≥1	Over the 4 weeks of treatment
Straining	The change from baseline in daily numerical rating scale scored as 0 (none), 1 (slight), 2 (mild), 3 (moderate) and 4 (severe) scores averaged over each treatment week for straining will be compared between the 2 groups	4 weeks
IBS-QOL	assess change in IBS-QOL from baseline and the last week of treatment week 4	baseline and week 4
HADS score	assess change in HADS score from baseline and the last week of treatment of week 4	baseline and week 4
WPAI questionnaire	assess change in WPAI questionnaire from baseline and the last week of treatment of week 4	baseline and week 4
Sleep Assessment questionnaire	assess change in Sleep Assessment questionnaire from baseline and the last week of treatment of week 4	baseline and week 4

Collaborators and Investigators

• Sponsor: University of Michigan
• Investigators: Principal Investigator: Stacy B Menees, MD, MS, University of Michigan

Study record dates

Study Major Dates

• Study Start (Actual): November 8, 2018
• Primary Completion (Anticipated): December 31, 2023
• Study Completion (Anticipated): December 31, 2023

Study Registration Dates

• First Submitted: September 25, 2018
• First Submitted That Met QC Criteria: September 26, 2018
• First Posted (Actual): September 27, 2018

Study Record Updates

• Last Update Posted (Actual): January 20, 2023
• Last Update Submitted That Met QC Criteria: January 18, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Disease; Signs and Symptoms, Digestive; Gastrointestinal Diseases; Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Syndrome; Irritable Bowel Syndrome; Constipation; Gastrointestinal Agents; Laxatives; Polyethylene glycol 3350
• Other Study ID Numbers: HUM00139784

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No